A Bedside-to-Bench Approach to Pandemic Preparedness

内布拉斯加大学医学中心（UNMC）的临床能力及其 临床合作伙伴内布拉斯加医学（NM）在美国公民的治疗中发挥了重要作用 2014年感染埃博拉病毒以及对COVID-19大流行的早期反应。而 国家检疫单位（NQU）和内布拉斯加州生物防护单位（NBU）的存在 在校园里，UNMC的研究人员最早接触到了一些受感染的人。 传染源（在NQU），以及那些开始发展疾病的人（在NBU）， 我们认识到，我们能力的一个关键差距是，在我们的高科技领域缺乏现代技术， 所需的遏制空间，以获得更深入的了解致病机制所利用的 新出现的病原体。因此，本拟议项目的总体目标是实现现代化 我们的高防护研究实验室，以最大限度地发挥其研究潜力，并利用 我们的临床专业知识，以促进疫苗和治疗开发的研究。这将是 我们将通过两种方式来实现：首先，我们将在关键领域改善我们的生物遏制基础设施， 生物遏制研究设施，以提高我们进行研究的能力， 高后果的病原体，最大限度地发挥各种生物遏制之间的协同作用， 实验室，并加强生物安全。第二，我们将投资于所需的现代技术 在我们的BSL-3和ABSL-3实验室进行新的和新兴的前沿研究 病原体，并解决与疾病发病机制有关的关键问题。完成后， 这些改进将促进临床和研究部门之间更大的协同作用， 联合国监测委员会和地中海管理局，利用抢先体验获得临床数据/样本的机会， 疾病的发病机理，并加快新疫苗和治疗方法的开发 在未来的流行病中。

The clinical capabilities of the University of Nebraska Medical Center (UNMC) and its clinical partner, Nebraska Medicine (NM), played vital roles in the treatment of U.S. citizens infected with Ebola in 2014 and the early response to the COVID-19 pandemic. While the presence of the National Quarantine Unit (NQU) and the Nebraska Biocontainment Unit (NBU) on campus provided UNMC researchers with some of the earliest access to individuals exposed to infectious agents (in the NQU), as well as those who begin to develop disease (in the NBU), we recognized a key gap in our capabilities is the lack of modern technologies within our high- containment spaces required to gain greater insights into the pathogenic mechanisms utilized by new and emerging pathogens. Therefore, the overall goal of this proposed project is to modernize our high-containment research laboratories to maximize their research potential and to leverage our clinical expertise to foster research on vaccine and therapeutic development. This will be achieved in two ways: First, we will improve our biocontainment infrastructure within key biocontainment research facilities in a way that increases our capacity to conduct research on high-consequence pathogens, maximizes synergy between the various biocontainment laboratories, and increases biosecurity. Second, we will invest in the modern technologies needed in our BSL-3 and ABSL-3 laboratories to conduct cutting-edge studies on new and emerging pathogens and to address critical questions related to disease pathogenesis. Upon completion, these improvements will foster much greater synergy between the clinical and research arms of UNMC and NM, leveraging early access to clinical data/samples to streamline research into disease pathogenesis, and to accelerate the development of new vaccines and therapeutics during future pandemics.